As US medical device maker Medtronic looks to gain a stronger footing against the market’s top competitor Johnson & Johnson, reports say Medtronic has offered concessions to EU authorities to secure approval for its buyout plans.
Medtronic is seeking to acquire Irish rival Covidien for $43 billion. According to reports, that takeover would place Medtronic at a nearly even level with Johnson & Johnson and lessen its tax burden.
The European Commission said this week that Medtronic has submitted concessions for the deal, but declined to say what those concessions are. The watchdog said it will rule on the merger by November 28.
Earlier reports said Covidien was willing to sell certain assets to close the deal.
Medtronic is looking to increase its competitive edge and has denied any claims that the merger is an inversion deal aimed at lowering its tax rates, though the merger would accomplish just that.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan